Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes

Index60 as an additional diagnostic criterion for type 1 diabetes

(2021) Maria J. Redondo et al.   DIABETOLOGIA

The clinical consequences of heterogeneity within and between different diabetes types

(2020) Maria J. Redondo et al.   DIABETOLOGIA

One-Hour Oral Glucose Tolerance Tests for the Prediction and Diagnostic Surveillance of Type 1 Diabetes

(2020) Kimber M Simmons et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes

(2019) Manuela Battaglia et al.   DIABETES CARE

2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020

(2019)   DIABETES CARE

One hour post-OGTT glucose improves the early prediction of type 2 diabetes by clinical and metabolic markers

(2018) Gopal Peddinti et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Adult-onset autoimmune diabetes: current knowledge and implications for management

(2017) Raffaella Buzzetti et al.   Nature Reviews Endocrinology

Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012

(2017) Elizabeth J. Mayer-Davis et al.   NEW ENGLAND JOURNAL OF MEDICINE

HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression

(2016) Alberto Pugliese et al.   DIABETES

The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants

(2016) Farah A. Meah et al.   DIABETOLOGIA

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

(2015) Richard A. Insel et al.   DIABETES CARE

The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study

(2015) Jeffrey P. Krischer et al.   DIABETOLOGIA

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes

(2014) Jay M. Sosenko et al.   DIABETES CARE

A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History

(2014) Jay M. Sosenko et al.   DIABETES CARE

The use of intermediate endpoints in the design of type 1 diabetes prevention trials

(2013) Jeffrey P. Krischer et al.   DIABETOLOGIA

Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children

(2013) Anette G. Ziegler et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The many faces of diabetes: a disease with increasing heterogeneity

(2013) Tiinamaija Tuomi et al.   LANCET

Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study

(2011) Jay M. Sosenko et al.   DIABETES CARE

Development of Autoantibodies in the TrialNet Natural History Study

(2011) K. Vehik et al.   DIABETES CARE

HLA Class I and Genetic Susceptibility to Type 1 Diabetes: Results From the Type 1 Diabetes Genetics Consortium

(2010) J. A. Noble et al.   DIABETES

Epidemiology of Type 1 Diabetes

(2010) David M. Maahs et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants

(2009) J. M. Sosenko et al.   DIABETES CARE

Gender differences and temporal variation in the incidence of type 1 diabetes: results of 8012 cases in the nationwide Diabetes Incidence Study in Sweden 1983–2002

(2008) J. Östman et al.   JOURNAL OF INTERNAL MEDICINE

The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results

(2008) Jeffrey L Mahon et al.   PEDIATRIC DIABETES